Since you asked to keep you posted i've had a few email exchanges with Revive (MF). I'm paraphrasing because i never asked for permission to post the entirety of his emails.
His reply was that i should speak to and argue with the FDA because they're the governing body. He gave examples of other companies that had difficulties trying to get through to the FDA. And, shareholders knew the risks.
I responded with "A poorly designed clinical trial is not the FDA’s fault, the fault falls on Revive’s management."
In reply MF stated that the trial was designed with hospitalization and the environment changed.
In response i stated that for shareholder's sake i hope Revive has a good plan for moving forward.